Paper Details

  1. Home
  2. Paper Details

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.

Author: BenattiaIsma, BrookShlomo, RomanoSteven J, SiuCynthia O, WaldenJeorg

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Ziprasidone is more effective and has better tolerability than haloperidol in treating acute schizophrenia, with significantly better outcomes for negative symptoms. However, both drugs had similar effectiveness at the end of treatment.
Paper Details　
Original Abstract of the Article :
RATIONALE: Conventional intramuscular (IM) antipsychotics used in managing acute exacerbation of schizophrenia are associated with side effects such as acute dystonia. OBJECTIVES: To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of sc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00213-004-2082-5

データ提供：米国国立医学図書館（NLM）

Comparing Ziprasidone and Haloperidol for Acute Schizophrenia

The field of [psychiatry] is constantly seeking more effective and tolerable treatments for [mental health conditions] like [schizophrenia]. This study compares the efficacy and tolerability of [ziprasidone] and [haloperidol] in treating [acute exacerbation of schizophrenia or schizoaffective disorder]. This is a [randomized, blinded-assessment study] that examines the effectiveness of these two antipsychotic medications in managing [acute psychiatric symptoms].

The study found [that ziprasidone showed significant improvements in psychiatric symptoms compared to haloperidol, with fewer extrapyramidal side effects]. This finding highlights the potential of [ziprasidone] as a more effective and tolerable treatment option for [acute schizophrenia] compared to [haloperidol].

Finding a More Tolerable Oasis in the Desert of Schizophrenia Treatment

This study suggests that [ziprasidone] may be a more effective and tolerable treatment option for [acute schizophrenia] compared to [haloperidol]. This finding could have a significant impact on patient care, potentially leading to improved treatment outcomes and fewer side effects.

Navigating the Desert of Mental Health

It's essential to remember that [mental health] is a complex issue, and individual responses to treatment can vary. This study underscores the importance of ongoing research and development of new and improved treatment options for [mental health conditions]. It also emphasizes the importance of consulting with a qualified mental health professional for personalized care and support.

Dr. Camel's Conclusion

This study is a beacon of hope in the desert of [schizophrenia] research. The finding that [ziprasidone] may be a more effective and tolerable treatment option for [acute schizophrenia] compared to [haloperidol] is a significant step forward. It’s a reminder that we’re constantly striving to improve treatment options for those navigating the challenges of [mental health conditions].

Date :
  1. Date Completed 2005-10-20
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

15650846

DOI: Digital Object Identifier

10.1007/s00213-004-2082-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.